Abstract 2271
Background
No previous study has evaluated the prognostic value of coagulation factors in patients with early-stage natural killer/T-cell lymphoma (NKTCL). The aim of this study was to investigate the relationships between coagulation function and clinical response and prognosis in patients with early-stage NKTCL.
Methods
The data of patients with stage I/II NKTCL who were treated in Cancer Hospital, Chinese Academy of Medical Sciences from January 2008 to January 2019 were collected and studied retrospectively. Data included patients’ clinical characteristics and related indexes of coagulation function before treatment (preoperative activated partial thromboplastin time (APTT), prothrombin time (PT), prothrombin time activity (PTA), fibrinogen (FIB), international normalized ratio (INR), D-dimer, and platelet count (PLT)). The cut-off value was set as the median of pretreatment coagulation factors.
Results
A total of 159 patients with stage I/II NKTCL were included in this study. Abnormal coagulation function was found in nearly half of (49.69%) patients, and increased D-dimer(16.28%) and FIB(11.25%) were the most common abnormalities. Univariate analysis showed that increased D-dimer level (P < 0.001) and increased FIB level (P = 0.021) reduced complete remission (CR) rate. In addition to other prognostic factors including Eastern cooperative oncology group (ECOG) score≥2, B symptom, increased lactate dehydrogenase (LDH) level, increased D-dimer level was also demonstrated to be associated with the unfavorable progression-free survival (PFS) (P = 0.003) and overall survival (OS) (P = 0.002). Multivariate analysis indicated that increased D-dimer level was an independent factor for poor clinical response (P = 0.008), PFS (P = 0.021) and OS (P = 0.007).
Conclusions
Our study suggested that elevated pretreatment coagulation factors especially D-dimer and plasma FIB were unfavorable predictors for clinical response, OS and PFS in early-stage NKTCL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dong Mei.
Funding
The Cancer Foundation of China, Beijing Hope Marathon Project Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract